ABBV-399

DRUG2 trials

Sponsors

AbbVie, SWOG Cancer Research Network

Conditions

Advanced Solid Tumors CancerRecurrent Squamous Cell Lung CarcinomaStage IV Squamous Cell Lung Carcinoma AJCC V7

Phase 1

A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors

CompletedNCT03311477

AbbVieAdvanced Solid Tumors Cancer

Start: 2017-11-06End: 2019-03-04Updated: 2019-03-14

Phase 2

Lung-MAP S1400K: c-MET Positive

CompletedNCT03574753

SWOG Cancer Research NetworkRecurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC V7

Start: 2018-03-16End: 2021-07-30Updated: 2021-10-18

Related Papers

MYTX-011: A pH-Dependent Anti–c-MET Antibody–Drug Conjugate Designed for Enhanced Payload Delivery to c-MET–Expressing Tumor Cells

Molecular Cancer Therapeutics2024-04-269 citations

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer

JAMA Oncology2021-07-1596 citations

Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors

Cancer Medicine2021-03-0611 citations

Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753).

Journal of Clinical Oncology2019-05-205 citations